send mail to firstname.lastname@example.org mentioning your email id and mobileno registered with us! if details not recieved
Resend Opt after 60 Sec.
Please verify your mobile number
Subscribe to Notifications
Stay updated with the latest Current affairs and other important updates regarding video Lectures, Test Schedules, live sessions etc..
Refer & Earn
My Abhipedia Earning
Kindly Login to view your earning
The Drugs Controller General of India (DGCI) gave nod for Phase-2 and Phase-3 trails of India’s first mRNA-based COVID-19 vaccine.A vaccine developed using mRNA technology is aimed at training immunity cells to fight Covid-19 using genetic instructions.
India’s first mRNA vaccine candidate, HGCO19 has been developed by Gennova Biopharmaceuticals Ltd. in collaboration with HDT Biotech Corporation of USA. Vaccine has demonstrated safety, immunogenicity, neutralization antibody activities among rodent and non-human primate models. It has successfully conducted the phase one trial and will undergo phase 2 and phase 3 trials.
m-RNA Vaccines work by training the body in order to recognise and respond to the proteins that are produced by disease-causing organisms like virus or bacteria. mRNA vaccines trick the body to produce viral proteins itself. They work by using messenger RNA (m-RNA) which is the molecule that puts DNA instructions into action. mRNA is used as a template to build protein inside a cell.
Traditional vaccines are made up of small or inactivated doses of disease-causing organism, or proteins produced by it. These inactivated organisms are introduced into the body in order to boost the immune system so that it responds against the disease-causing organisms.
By: Brijesh Kumar ProfileResourcesReport error
Access to prime resources